Skip to main content

Advertisement

Table 1 Clinical characteristics of patients, before and during ezetimibe treatment

From: NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

  Baseline 6 months 12 months
Body mass index (kg/m2) 23.03 ± 2.04 22.81 ± 2.34 22.84 ± 2.17
ALT (IU/L) 70.13 ± 24.61 36.64 ± 19.41* 34.25 ± 12.61*
GGT (IU/L) 115.00 ± 62.28 69.50 ± 28.49 68.38 ± 28.28
Total cholesterol (mg/dL) 212.00 ± 49.01 192.25 ± 30.68* 191.38 ± 28.61*
Triglyceride (mg/dL) 98.88 ± 34.22 89.88 ± 31.56 94.88 ± 30.62
HDL-cholesterol (mg/dL) 59.13 ± 11.81 58.25 ± 12.09 61.50 ± 12.51
LDL-cholesterol (mg/dL) 137.50 ± 34.59 113.13 ± 29.68* 111.00 ± 29.65*
HOMA-IR 2.31 ± 0.25 2.24 ± 0.14 2.17 ± 0.31
  1. Data are shown as mean ± SD
  2. ALT, alanine aminotransferase; GGT, γ-glutamyl transpeptidase; HOMA-IR, homeostasis model assessment-insulin resistance
  3. *p < 0.05 compared with baseline